Results 41 to 50 of about 364,936 (336)
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern +7 more
wiley +1 more source
Early assessment and mitigation of non-clinical immunogenicity risk during early drug development is key for the development of safe and efficacious therapeutics.
Chloé Ackaert +6 more
doaj +1 more source
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece +18 more
wiley +1 more source
Tumor derived Microvesicles enhance cross-processing ability of clinical grade Dendritic Cells [PDF]
Tumor cells release extracellular microvesicles (MVs) in the microenvironment to deliver biological signals to neighbouring cells as well as to cells in distant tissues.
Battisti, Federico +11 more
core +1 more source
Background: International Society on Thrombosis and Haemostasis guidelines for immune-mediated thrombotic thrombocytopenic purpura (iTTP) treatment recommend concurrent therapeutic plasma exchange (TPE), immunosuppressive therapy (IST), and caplacizumab.
Brendy Van Butsel +6 more
doaj +1 more source
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source
The use of the MAPPs (Major histocompatibility complex Associated Peptide Proteomics) assay by pharmaceutical companies, service providers, and academic laboratories is rapidly increasing, attesting to its increasingly pivotal role in biotherapeutic drug
A.C. Karle +8 more
doaj +1 more source
TREX1, a predator for treating MSI‐H tumors?
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya +2 more
wiley +1 more source
Inhibition of HIF-1 alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma [PDF]
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are ...
Acland +49 more
core +1 more source
Immunogenicity of sulfatide [PDF]
Abstract The present study deals with the immunogenicity of sulfatide. Despite its acidic character, we succeeded in raising high titer antibodies. The most effective immunization procedure involved repeated intravenous injections of a mixture of sulfatide-lecithin-cholesterol-methylated bovibe serum albumin (1:4:10:10).
Zalc, B. +3 more
openaire +3 more sources

